<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="62102">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01936636</url>
  </required_header>
  <id_info>
    <org_study_id>RELIEF</org_study_id>
    <nct_id>NCT01936636</nct_id>
  </id_info>
  <brief_title>Observational Registry Study of Quality of Life When Treating BTcP With Abstral</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>Rapid Evaluation of Lifestyle, Independence, and Elimination of Breakthrough Cancer Pain With Freedom From Oral Discomfort Through the Use of Abstral® (Fentanyl) Sublingual Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galena Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galena Biopharma, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Observational Registry study is designed to collect self-reported Transmucosal
      Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access
      program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of
      treatment with Abstral® through the use of Quality of Life and pain measurement tools
      administered via questionnaire.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a post-marketing, single arm, open label multicenter trial to assess Abstral
      (fentanyl) Sublingual Tablets for breakthrough cancer pain (BTcP) in opioid-tolerant cancer
      patients.

        -  Prior to study enrollment, patient enrollment in the TIRF REMS Access program must be
           confirmed.

        -  Eligible patients will sign written informed consent.  Patients or their proxy with a
           witness must be able to sign written informed consent to participate in the study; and
           the patient may use a proxy caregiver to assist in the completion of the study
           questionnaires.

        -  Day 0, study site must enroll patient by completing a patient demographic profile
           (de-identified).

        -  Day 0, patient will be instructed how to use the questionnaires.

        -  Day 0, patient will complete the baseline questionnaire before leaving the physician
           office.

        -  On study Days 14, 21, and 28 (±3 days) patient questionnaire will be completed by
           patient (or caregiver proxy) via secure online data entry portal.

        -  For patients completing paper questionnaires, within 1 month of day 28, patient will
           return completed questionnaires via mail, fax or hand carried to the study site
           coordinator for processing.

        -  Patient will be considered to have completed the study successfully once all completed
           questionnaires have been received by the CRO within appropriate time limits.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Time Perspective: Prospective</study_design>
  <target_duration>4 Weeks</target_duration>
  <primary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>One month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Primary:
To compare self reported TIRF REMS Access-enrolled patient experience with BTcP at baseline (before using Abstral) to their experience after reaching a maintenance dose of Abstral
Characterize the effectiveness of treatment with Abstral in select pain and quality-of-life (QoL) domains
Abstral impact on pain interference with daily activities, somnolence, and oral health</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rapidity of BTcP</measure>
    <time_frame>one month</time_frame>
    <safety_issue>No</safety_issue>
    <description>Trends in improvement or deterioration in these values during treatment and across the dosage groups will be described.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2500</enrollment>
  <condition>Quality of Life</condition>
  <condition>Breakthrough Cancer Pain</condition>
  <arm_group>
    <arm_group_label>Cancer patients treated for BTcP</arm_group_label>
    <description>All patients 18 years of age and older with breakthrough cancer pain (BTcP) who are registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction of a TIRF REMS Access program-registered physician are eligible for the study.
Patients or their proxy with a witness must be able to sign written informed consent to participate in the study; and the patient may also use a proxy caregiver to assist in the completion of the study questionnaires.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Cancer patients treated for BTcP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This observational Registry study is designed to collect self-reported TIRF REMS Access
        program-enrolled patient experience with breakthrough cancer pain (BTcP) as a result of
        treatment with Abstral® through the use of Quality of Life and pain measurement tools
        administered via questionnaire.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients 18 years of age and older with breakthrough cancer pain who are
             registered in the Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and
             Mitigation Strategy (REMS) Access program and receiving Abstral® under the direction
             of a TIRF REMS Access program-registered physician are eligible for the study.

        Patients or their proxy with a witness must be able to sign written informed consent to
        participate in the study; and the patient may also use a proxy caregiver to assist in the
        completion of the study questionnaires.

        Exclusion Criteria:

          -  No patient can be enrolled who has not been prescribed Abstral for BTcP in compliance
             with Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation and Mitigation
             Strategy (REMS) Access program guidelines.

        No patient may be enrolled who has a contraindication to receiving Abstral or who is
        pregnant.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Allan Valmonte</last_name>
    <phone>+1.503.400.6624</phone>
    <email>avalmonte@galenabiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Physicians Pain Specialists of Alabama, P.C.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neil Stimpson, CCRC</last_name>
      <phone>251-382-1823</phone>
      <email>sunbeltresearch@comcast.net</email>
    </contact>
    <investigator>
      <last_name>John Couch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley Pain Consultants</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85254</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vicky Yaro</last_name>
      <phone>480-991-3005</phone>
      <email>victoriay@valleyanesth.org</email>
    </contact>
    <investigator>
      <last_name>Nikesh Seth, mD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Navajo Road Pain Management Center</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Moreno, RN</last_name>
      <phone>619-287-7246</phone>
      <phone_ext>202</phone_ext>
      <email>arelyvicky@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Naga Roja Thota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interventional Pain Management</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92618</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Don Mills, MD</last_name>
      <phone>949-502-5777</phone>
      <email>donfmillsfamily@cox.net</email>
    </contact>
    <contact_backup>
      <last_name>Raif Iskander, MD</last_name>
      <phone>949-502-5777</phone>
      <email>raifskanderpac@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Don Mills, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Raif Iskander, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Institute of Santa Monica</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerald Sacks, MD</last_name>
      <phone>310-264-7314</phone>
      <email>g_sacks@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Red Rocks Center for Rehabilitation</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Kesten, MD</last_name>
      <phone>303-277-0700</phone>
      <email>rrpaincenter@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Kesten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Western Connecticut Health Network, Danbury Hospital</name>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <zip>06810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara Turner</last_name>
      <phone>203-739-6985</phone>
      <email>barbara.turner@wchn.org</email>
    </contact>
    <investigator>
      <last_name>Robert Kloss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pain Management Associates of CT, PC</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Asken</last_name>
      <phone>203-325-5700</phone>
      <email>rasken@paindoctors.net</email>
    </contact>
    <investigator>
      <last_name>Vincent Carlesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Interventional Spine and Pain Management</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Rosenfeld, MD</last_name>
      <phone>404-554-0633</phone>
      <email>atlpain@gmail.com</email>
    </contact>
    <investigator>
      <last_name>David Rosenfeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Treatment Centers of America</name>
      <address>
        <city>Newnan</city>
        <state>Georgia</state>
        <zip>30265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matt Maxwell, RN</last_name>
      <phone>770-400-6655</phone>
      <email>matt.maxwell@ctca-hope.com</email>
    </contact>
    <investigator>
      <last_name>Nathan Neufeld, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Physiatry Consultants</name>
      <address>
        <city>Bay City</city>
        <state>Michigan</state>
        <zip>48796</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Villano, FNP</last_name>
      <phone>989-667-6662</phone>
      <email>pjtvill@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Lakkaraju, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Interventional Pain Center</name>
      <address>
        <city>Brownstown</city>
        <state>Michigan</state>
        <zip>48183</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Tluczek</last_name>
      <phone>734-479-7246</phone>
      <email>mptlucxek@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Razmig A. Haladjian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gavin I. Awerbuch, MD</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gavin Awerbuch, MD</last_name>
      <phone>989-791-7999</phone>
      <email>gavinia@aol.com</email>
    </contact>
    <investigator>
      <last_name>Gavin I Awerbuch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Spine &amp; Pain</name>
      <address>
        <city>West Bloomfield</city>
        <state>Michigan</state>
        <zip>48322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bleiberg, RN</last_name>
      <phone>248-851-7223</phone>
      <phone_ext>1005</phone_ext>
      <email>ebleiberg@michiganspineandpain.com</email>
    </contact>
    <investigator>
      <last_name>Marvin Bleiberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upper East Side Pain Medicine, P.C.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>36607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim Best, RN</last_name>
      <phone>212-288-2180</phone>
    </contact>
    <investigator>
      <last_name>Gordon Freedman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Pain Management</name>
      <address>
        <city>Syosset</city>
        <state>New York</state>
        <zip>11791</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marissa French, RN</last_name>
      <phone>516-496-4964</phone>
      <phone_ext>25</phone_ext>
      <email>frenchcpm@aol.com</email>
    </contact>
    <investigator>
      <last_name>Alexander Weingarten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Akron General Medical Center</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Gerber, RN</last_name>
      <phone>330-344-1171</phone>
      <email>amy.gerber@akrongeneral.org</email>
    </contact>
    <investigator>
      <last_name>John Petrus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jerrold Rosenberg, MD</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Gaumond, RN</last_name>
      <phone>401-453-5030</phone>
      <email>egaumond@jrmd.net</email>
    </contact>
    <investigator>
      <last_name>Jerrold Rosenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The West Clinic Comprehensive Breast Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Roper, RN</last_name>
      <phone>901-683-0055</phone>
      <phone_ext>2127</phone_ext>
      <email>aroper@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Seth Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRIDE</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eliza Garcia</last_name>
      <phone>214-389-6656</phone>
      <email>elizagarcia@pridedallas.com</email>
    </contact>
    <investigator>
      <last_name>Howard Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Benny J. Sanchez, MD</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan K Smith, RN</last_name>
      <phone>713-697-6884</phone>
      <email>sksmith@bennyjsanchezmd.com</email>
    </contact>
    <investigator>
      <last_name>Benny J Sanchez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia Basin Hematology &amp; Oncology</name>
      <address>
        <city>Kennewick</city>
        <state>Washington</state>
        <zip>99336</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Johansen</last_name>
      <phone>509-783-0144</phone>
      <email>hjohansen@cbho.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Rado, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 24, 2014</lastchanged_date>
  <firstreceived_date>September 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breakthrough cancer pain</keyword>
  <keyword>diary</keyword>
  <keyword>quality of life</keyword>
  <keyword>Abstral</keyword>
  <keyword>BTcP</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
